Baird Starts Beta Bionics, Inc. (BBNX) at Neutral

Baird analyst Jeff Johnson initiates coverage on Beta Bionics, Inc. (NASDAQ: BBNX) with a Neutral rating and a price target of $20.00.

The analyst comments "Initiating coverage of Beta Bionics (BBNX) with Neutral rating/$20 price target. While we believe Beta's iLet Bionic Pancreas is differentiated, and we're bullish on the multi-year growth potential for the insulin pump market, we also believe iLet will likely carve out more of a niche domestic AID market share position and worry iLet's ease-of-use pump initialization/mealtime competitive advantages could narrow over time. With shares trading ~2x smid-cap medtech growth peer group median, we view risk/reward balanced and would need to see pull-back for shares to mid-teens to turn more constructive."

For an analyst ratings summary and ratings history on Beta Bionics, Inc. click here. For more ratings news on Beta Bionics, Inc. click here.

Shares of Beta Bionics, Inc. closed at $21.96 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Invitation Homes (INVH) to Overweight
• Leerink Starts Rapport Therapeutics (RAPP) at Outperform
• Cantor Fitzgerald Starts Silence Therapeutics (SLN) at Overweight